Washington, D.C. 20549
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
On November 17, 2026, Enlivex Ltd., a company organized under
the laws of the State of Israel (the “Company”), announced that it will hold an Extraordinary General Meeting of Shareholders
of the Company (the “Meeting”) on Friday, December 4, 2026, beginning at 10:00 a.m. Israel time, at the offices of
the Company located at 14 Einstein Street, Nes Ziona, Israel 7403618. Copies of the notice and proxy statement and the related proxy card
are attached to this Report on Form 6-K as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference.
The information contained
in this Report on Form 6-K, including Exhibits 99.1 and 99.2, is hereby incorporated by reference into the Company’s registration
statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799,
File No. 333-232413,
File No. 333-232009,
File No. 333-252926,
File No. 333-286956, File No.
333-292417, File No. 333-294284,
File No. 333-295215 and File
No. 333-298071), filed with
the U.S. Securities and Exchange Commission.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Exhibit 99.1
ENLIVEX LTD.
NOTICE OF EXTRAORDINARY GENERAL MEETING OF
SHAREHOLDERS
To be held on December 4, 2026
Dear Shareholder:
We cordially invite you to attend an Extraordinary General Meeting
of Shareholders (the “Meeting”) of Enlivex Ltd. (the “Company”) to be held on Friday, December 4,
2026, at 10:00 a.m. (Israel time), at the offices of the Company at 14 Einstein Street, Ness Ziona, Israel 7403618.
The purpose of the Meeting
is to vote on a proposal to approve an increase in the Company’s authorized share capital and to amend the Company’s Articles
of Association accordingly.
Our Board of Directors
recommends that you vote “FOR” the foregoing proposal, which is described in the attached proxy statement.
Shareholders of record at the close of business on November 20, 2026
(the “Record Date”) are entitled to notice of and to vote at the Meeting and any adjournments or postponements thereof.
You are also entitled to vote at the Meeting if you held ordinary shares through a bank, broker or other nominee that was a shareholder
of record at the close of business on the Record Date or which appeared in the participant listing of a securities depository on that
date.
Whether or not you plan to
attend the Meeting, you are urged to vote your shares: (1) by telephone, (2) through the Internet or (3), if you received printed copies
of the proxy materials, by promptly completing, dating and signing the enclosed proxy card and mailing it in the enclosed envelope, which
requires no postage if mailed within the United States. For specific instructions on how to vote your shares, please refer to the Notice
of Internet Availability of Proxy Materials (the “Notice”) that will be mailed to beneficial owners of our ordinary shares,
the section titled “How You Can Vote” of the proxy statement, the proxy card or the instructions provided by your broker,
bank, trustee or nominee, as applicable.
A mailed proxy must be received by our transfer agent or at our registered
office in Israel no later than 10:00 a.m. (Israel time) on December 1, 2026, to be validly included in the tally of ordinary shares voted
at the Meeting. Return of your proxy does not deprive you of your right to attend the Meeting, to revoke your proxy or to vote your shares
in person at the Meeting.
The presence (in person or
by proxy) of any two or more shareholders holding, in the aggregate, at least twenty-five percent (25%) of the voting rights of the Company
constitutes a quorum for purposes of the Meeting. If such quorum is not present within an hour from the time scheduled for the Meeting,
the Meeting will be adjourned to the following week, to the same day, time, and place, without it being necessary to notify our shareholders.
At such an adjourned meeting, the presence of any two shareholders (in person or by proxy) (regardless of the voting power represented
by their ordinary shares) will constitute a quorum.
The last date for submitting a request to include a proposal for consideration
at the Meeting in accordance with Section 66(b) of the Israeli Companies Law, is November 24, 2026. Shareholders may review the full version
of the proposed resolutions in the accompanying proxy statement as well as the accompanying proxy card, at www.proxyvote.com as described
in the Notice, via the website of the U.S. Securities and Exchange Commission at www.sec.gov and at the “Investor Relations”
portion of our website, which can be found at www.enlivex.com, and also at the Company’s offices, upon prior notice and during
regular working hours (14 Einstein Street, Ness Ziona, Israel 7403618; Tel: +972-8-6380301 (phone)), until the date of the Meeting. The
information contained on, or accessible through, the foregoing websites is not incorporated by reference in, and does not form a part
of, this notice or the accompanying proxy statement.
| |
By Order of the Board of Directors, |
| |
|
| |
/s/
Shai Novik |
| |
Shai Novik |
| |
Executive Chairman of the Board of Directors |
| |
| November 17, 2026 |
ENLIVEX LTD.
14 Einstein Street,
Ness Ziona 7403618
Israel
PROXY STATEMENT
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
To be held
on December 4, 2026
This proxy statement is being furnished in connection with the solicitation
of proxies on behalf of the Board of Directors of Enlivex Ltd. (“we,” “us,” “our”
or the “Company”) to be voted at an Extraordinary General Meeting of Shareholders (the “Meeting”),
or at any adjournment or postponement thereof, pursuant to the accompanying Notice of Extraordinary General Meeting of Shareholders. The
Meeting will be held on Friday, December 4, 2026, at 10:00 a.m. (Israel time) at the offices of the Company at 14 Einstein Street, Ness
Ziona, Israel 7403618.
You are entitled to receive notice of, and vote at, the Meeting if
you were a shareholder of record at the close of business on November 20, 2026 (the “Record Date”). Subject to the
terms described herein, you are also entitled to vote at the Meeting if you held ordinary shares through a bank, broker or other nominee
that was a shareholder of record at the close of business on the Record Date or which appeared in the participant listing of a securities
depository on that date. See below “How You Can Vote.”
Purpose of the Extraordinary General Meeting
At the Meeting, shareholders
of the Company will be asked to consider and vote on a proposal to approve an increase in the Company’s authorized share capital
and to amend the Company’s Articles of Association accordingly.
We are not aware of any other matters that will come before the Meeting. If any other matters properly come before the Meeting, the person
designated as proxy intends to vote on such matters in accordance with her best judgment in the best interests of the Company.
Board Recommendation
Our Board of Directors unanimously
recommends that you vote “FOR” the above proposal, which is described in greater detail elsewhere in this Proxy Statement.
Quorum and Adjournment
The presence (in person or
by proxy) of any two or more shareholders holding, in the aggregate, at least twenty-five percent (25%) of the voting rights of the Company
constitutes a quorum for purposes of the Meeting. If such quorum is not present within an hour from the time scheduled for the Meeting,
the Meeting will be adjourned to the following week, to the same day, time and place, without it being necessary to notify our shareholders.
At such an adjourned meeting, the presence of any two shareholders (in person or by proxy) (regardless of the voting power represented
by their ordinary shares) will constitute a quorum.
Abstentions and broker non-votes
will be counted for purposes of determining the presence of a quorum, but they will not have an effect on the outcome of the proposal.
Broker non-votes occur when brokers that hold their customers’ shares in street name sign and submit proxies for such shares (in
which case they are considered present for purposes of determining the presence of a quorum at the Meeting) but do not have the discretionary
authority to vote on the proposal. Brokers that have not received voting instructions from their customers may vote such shares, as the
holders of record, on “routine” matters but not on “non-routine” matters. The proposal constitutes a “routine”
matter.
Unsigned or unreturned proxies,
including those not returned by banks, brokers, or other record holders, will not be counted for quorum or voting purposes.
How You Can Vote
| ● | Voting
in person. If your shares are registered directly in your name with our transfer agent (i.e., you are a “registered shareholder”),
you may attend and vote in person at the Meeting. If you are a beneficial owner of shares registered in the name of your broker, bank,
trustee or nominee (i.e., your shares are held in “street name”), you are also invited to attend the Meeting; however, to
vote in person at the Meeting as a beneficial owner, you must first obtain a “legal proxy” from your broker, bank, trustee
or nominee, as the case may be, authorizing you to do so. If you vote by telephone or Internet, there is no need to vote again at the
Meeting unless you wish to revoke and change your vote. |
| |
● |
Voting by mailing your proxy. If you have received printed copies of the proxy materials, you may
submit your proxy by mail by completing, signing and mailing the enclosed proxy card in the enclosed, postage-paid envelope, or, for shares
held in street name, by following the voting instructions provided by your broker, bank, trustee or nominee. The proxy must be received
by our transfer agent or at our registered office in Israel by no later than 10:00 a.m. Israel time, on December 1, 2026, to be validly
included in the tally of ordinary shares voted at the Meeting. Upon the receipt of a properly signed and dated proxy in the form enclosed,
the person named as proxy therein will vote the ordinary shares represented thereby in accordance with the instructions of the shareholder
indicated thereon, or if no direction is indicated, in accordance with the recommendations of our Board of Directors. |
| ● | Voting by telephone
or Internet. If your shares are held in an account at a brokerage firm or bank or registered directly in your name with our
transfer agent, you may vote those shares by accessing the Internet website address, or by calling the telephone number, specified
in the Notice of Internet Availability of Proxy Materials, the instructions provided by your broker, bank, trustee or nominee or on
your proxy card (as applicable), instead of completing and signing the proxy itself. If your shares are held in an account at a
brokerage firm or bank, you may also call the telephone number specified in the instructions provided by your broker, bank, trustee
or nominee. Submitting a telephonic or Internet proxy will not affect your right to vote at the Meeting should you decide to attend
the Meeting. The telephone and Internet voting procedures are designed to authenticate shareholders’ identities, to allow
shareholders to give their voting instructions, and to confirm that shareholders’ instructions have been recorded properly.
The accompanying proxy card provides instructions on how to vote via telephone and the Internet. |
Vote Required for Approval of the Proposal
Each outstanding ordinary
share held by a shareholder is entitled to one vote on each matter submitted to a vote of our shareholders.
The approval of the proposal
requires the affirmative vote of a majority of the ordinary shares represented at the Meeting, whether in person or by proxy, and voting
on the proposal (excluding abstentions).
Change or Revocation of Proxy
If you are a shareholder
of record, you may change your vote at any time prior to the exercise of authority granted in the proxy by delivering a written notice
of revocation to us, by granting a new proxy bearing a later date, or by attending the Meeting and voting in person. Attendance at the
Meeting will not cause your previously granted proxy to be revoked unless you specifically so request. You may also revoke your proxy
and change your vote at any time before the final vote at the Meeting by voting again via the Internet or by telephone, as applicable.
If your shares are held in
“street name” through a broker, bank, trustee or other nominee, you may change your vote by submitting new voting instructions
to your broker, bank, trustee or nominee or, if you have obtained a legal proxy from your broker, bank, trustee or nominee giving you
the right to vote your shares, by attending the Meeting and voting in person.
Solicitation of Proxies
All expenses of this solicitation
will be borne by the Company. In addition to the solicitation of proxies by mail, directors, officers and employees of the Company, without
receiving additional compensation therefor, may solicit proxies by telephone, email, in person or by other means. Brokerage firms, nominees,
fiduciaries and other custodians have been requested to forward proxy solicitation materials to the beneficial owners of shares of the
Company held of record by such persons, and the Company will reimburse such brokerage firms, nominees, fiduciaries and other custodians
for reasonable out-of-pocket expenses incurred by them in connection therewith.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT
The following table sets
forth certain information as of November 10, 2026 (unless otherwise indicated below) regarding the beneficial ownership by: (i) each person
known to us to beneficially own more than 5% of our outstanding ordinary shares, based on public filings or information available to
us; (ii) each of our current directors and executive officers; and (iii) all of our current directors and executive officers as a group.
The percentage of ordinary shares beneficially owned is based on 1,532,077 ordinary shares issued and outstanding as of November 10, 2026.
Beneficial ownership is determined
in accordance with the rules of the U.S. Securities and Exchange Commission (“SEC”) and is generally based on whether
a person has voting or investment power with respect to the securities. Ordinary shares of the Company that may be acquired by an individual
or group pursuant to the exercise of the Company’s outstanding options, restricted share units (“RSUs”), warrants
or other rights held by such individual or group that are exercisable or will become exercisable within 60 days of November 10, 2026 are
deemed beneficially owned by such individual or group, and such shares are additionally deemed outstanding for the purposes of computing
the percentage of ordinary shares beneficially owned by such individual or group, but are not deemed outstanding for purposes of computing
the percentage of ordinary shares beneficially owned by any other individual or group shown in the table.
| | |
Number of Ordinary Shares Beneficially Owned | | |
Percentage of Ordinary Shares Beneficially Owned | |
| 5% Shareholders | |
| | |
| |
| Sobrinia Ltd. (1) | |
| 90,735 | | |
| 5.88 | % |
| Heaven Consulting Corp | |
| 78,334 | | |
| 5.11 | % |
| Directors and Officers | |
| | | |
| | |
| Shai Novik (2) | |
| 33,825 | | |
| 2.20 | % |
| Roger Pomerantz, M.D. (3) | |
| 634 | | |
| * | |
| Avri Havron, Ph.D. (4) | |
| 1,001 | | |
| * | |
| Gili Hart, Ph.D. (5) | |
| 323 | | |
| * | |
| Matteo Renzi | |
| — | | |
| — | |
| Oren Hershkovitz (6) | |
| 1,596 | | |
| * | |
| Shachar Shlosberger (7) | |
| 473 | | |
| * | |
| Einat Galmidi (8) | |
| 573 | | |
| * | |
| Amor-Baroukh Veronik (9) | |
| 327 | | |
| * | |
| All directors and executive officers as a group (9 persons) | |
| 38,752 | | |
| 2.52 | % |
| * |
Less than 1% of our outstanding
ordinary shares. |
| (1) |
Includes 12,274 ordinary shares issuable under currently exercisable pre-funded warrants. |
| (2) |
Includes 4,766 ordinary
shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, of which 554 options expire
in December 2033 and have an exercise price of $646, 606 options expire in December 2033 and have an exercise price of $1,493, 1,041
options expire in May 2030 and have an exercise price of $879, 1,041 options expire in May 2031 and have an exercise price of $2,935
and 1,524 options expire in November 2032 and have an exercise price of $1,282. |
| |
|
| (3) |
Includes 625 ordinary shares underlying options currently exercisable
or exercisable within 60 days from November 10, 2026, which expire in November 2032 and have an exercise price of $1,432, and 3 RSUs that
shall vest within 60 days from November 10, 2026. |
| (4) |
Includes 235 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, of which 221 options expire in December 2033 and have an exercise price of $646 and 14 options expire in November 2032 and have an exercise price of $1,282, and 1 RSU that shall vest within 60 days from November 10, 2026. |
| |
|
| (5) |
Includes 291 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, of which 277 options expire in December 2033 and have an exercise price of $646 and 14 options expire in November 2032 and have an exercise price of $1,282, and 1 RSU that shall vest within 60 days from November 10, 2026. |
| |
|
| (6) |
Includes 875 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026, of which 625 options expire in December 2033 and have an exercise price of $1,966 and 250 options expire in November 2032 and have an exercise price of $1,282. |
| |
|
| (7) |
Includes 120 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026. |
| |
|
| (8) |
Includes 146 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026. |
| |
|
| (9) |
Includes 174 ordinary shares underlying options currently exercisable or exercisable within 60 days from November 10, 2026. |
PROPOSAL 1
APPROVAL OF AN INCREASE IN THE COMPANY’S
AUTHORIZED SHARE CAPITAL AND A CORRESPONDING AMENDMENT TO THE COMPANY’S ARTICLES OF ASSOCIATION
Background
The Company’s authorized share capital is currently NIS 950,000,000,
divided into 9,895,833 ordinary shares with a nominal value of NIS 96.0 each. As of November 10, 2026, 1,532,077 ordinary shares were
issued and outstanding. In addition, as of such date, 77,867 ordinary shares were reserved for issuance under our Global Share Incentive
Plan (2014) and Global Share Incentive Plan (2019) (including shares underlying outstanding options and RSUs), and 30,782 ordinary shares
were reserved for issuance upon the exercise of outstanding warrants. Accordingly, as of such date, 8,255,107 ordinary shares remained
unissued, unreserved, and available for future issuances.
Under the Companies Law, a
company may not issue shares in excess of its authorized share capital. The Company seeks to increase its authorized share capital to
help ensure that it can support its corporate purposes and future business needs as they arise, including, without limitation, potential
public and private offerings of the Company’s ordinary shares, debt conversions or repayments, and other corporate purposes, which
may include, without limitation, potential strategic transactions, such as mergers (including reverse mergers or similar business combinations),
spin-offs, separations or other reorganizations of all or part of the Company’s business, acquisitions of other companies or assets,
or other transactions that may involve the issuance of ordinary shares, as well as for purposes of equity-based compensation grants under
existing or any future equity-based incentive plans adopted by the Company. Any such future issuances will be subject to the discretion
of our Board of Directors, unless shareholder approval is required under the Companies Law and/or under the Nasdaq Listing Rules (to the
extent the Company is not permitted to, or elects not to, rely on the home country practice exemption under such rules).
Accordingly, at the Meeting, and as recommended by our Board of Directors,
shareholders will be asked to approve an increase in the Company’s authorized share capital from NIS 950,000,000, divided into 9,895,833
ordinary shares with a nominal value of NIS 96.0 each, to NIS 9,120,000,000, divided into 95,000,000 ordinary shares with a nominal value
of NIS 96.0 each, and to amend Article 2.1 of the Company’s Articles of Association accordingly to reflect this change.
The proposed increase in
our authorized share capital would not affect the rights of the holders of currently outstanding ordinary shares. However, the possible
future issuance of ordinary shares, or securities convertible into, or exercisable for, ordinary shares, could affect our current shareholders
in a number of ways, including: (i) diluting the voting power of current holders of ordinary shares; (ii) diluting the market price of
the ordinary shares, to the extent that new ordinary shares are issued and sold at prices below the current trading price of the existing
ordinary shares, or, in the case of convertible securities, to the extent that such securities are convertible into, or exercisable for,
ordinary shares at prices below current trading prices; and (iii) diluting the book value per share of the outstanding ordinary shares.
Proposal
It is therefore proposed that the following
resolution be adopted at the Meeting:
“RESOLVED, to approve the increase in the Company’s
authorized share capital from NIS 950,000,000 divided into 9,895,833 ordinary shares with a nominal value of NIS 96.0 each, to NIS 9,120,000,000
divided into 95,000,000 ordinary shares with a nominal value of NIS 96.0 each, and to amend Article 2.1 of the Company’s Articles
of Association accordingly.”
Approvals Required
See “Vote Required
for Approval of the Proposal” above.
Board Recommendation
Our Board of Directors
recommends a vote “FOR” the approval of the increase in the Company’s authorized share capital and the corresponding
amendment to the Company’s Articles of Association.
OTHER BUSINESS
The Board of Directors is
not aware of any business to be transacted at the Meeting other than those described in this proxy statement. If any other matters are
properly brought before the Meeting, it is intended that the person named as proxy in the enclosed form of proxy will vote upon such
matters, pursuant to her discretionary authority, in accordance with her best judgment in the best interests of the Company.
ADDITIONAL INFORMATION
We are subject to the information
reporting requirements of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), applicable to foreign
private issuers, and we fulfill the obligations with respect to those requirements by filing reports with the SEC. Our SEC filings are
available to the public on the SEC’s website at www.sec.gov and under the “Investor Relations” section of our website
at www.enlivex.com. The contents of the foregoing websites do not form part of this Proxy Statement.
As a foreign private issuer,
we are exempt from the rules under the Exchange Act relating to the furnishing and content of proxy statements. The circulation of this
proxy statement and related notice should not be taken as an admission that we are subject to those proxy rules.
| |
By Order of the Board of Directors |
| |
|
| |
|
| |
Shai Novik |
| |
Executive Chairman of the Board of Directors |
November 17, 2026
7